

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

ATM (D2E2) Rabbit mAb

RRID:AB_2062659

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2873, RRID:AB_2062659

Antibody Information

URL: http://antibodyregistry.org/AB_2062659

Proper Citation: Cell Signaling Technology Cat# 2873, RRID:AB_2062659

Target Antigen: ATM (D2E2) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W

Antibody Name: ATM (D2E2) Rabbit mAb

Description: This monoclonal targets ATM (D2E2) Rabbit mAb

Target Organism: h, m, mouse, human

Antibody ID: AB_2062659

Vendor: Cell Signaling Technology

Catalog Number: 2873

Record Creation Time: 20250819T235253+0000

Record Last Update: 20250820T064224+0000

Ratings and Alerts

No rating or validation information has been found for ATM (D2E2) Rabbit mAb.

No alerts have been found for ATM (D2E2) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 79 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang P, et al. (2026) SKA2 promotes gastric cancer progression by regulating glutathione metabolism. *iScience*, 29(4), 115202.

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. *Cancer research*, 86(11), 2660.

Banerjee M, et al. (2026) FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. *Cancer research*, 86(10), 2522.

Alhourani F, et al. (2026) Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer. *Cancer research*, 86(1), 236.

Hung MY, et al. (2026) Pemetrexed potentiates ?? T cell-based immunotherapy in NSCLC through ATM-STING-NF-?B-mediated induction of NKG2D ligands. *International immunopharmacology*, 186, 117115.

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. *EMBO molecular medicine*, 18(6), 2322.

Sottnik JL, et al. (2026) Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. *Cancer research*, 86(7), 1605.

Dutta Chowdhury D, et al. (2026) TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. *Molecular cancer therapeutics*.

Miller KN, et al. (2025) p53 enhances DNA repair and suppresses cytoplasmic chromatin fragments and inflammation in senescent cells. *Nature communications*, 16(1), 2229.

Chiang JC, et al. (2025) Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair. *Science advances*, 11(11), eadt1241.

Zhou L, et al. (2025) Halting hepatocellular carcinoma: Identifying intercellular crosstalk in HBV-driven disease. *Cell reports*, 44(4), 115457.

Luo H, et al. (2025) Interleukin-33 (IL-33) promotes DNA damage-resistance in lung cancer. *Cell death & disease*, 16(1), 274.

Zhu X, et al. (2025) Circular RNA circATM binds PARP1 to suppress Wnt/ β -catenin signaling and induce cell cycle arrest in gastric cancer cells. *Journal of advanced research*.

Dufourd J, et al. (2025) TELS1 stabilizes t-loops independently of TRF2 and controls telomere length in pluripotent cells. *Cell reports*, 44(9), 116260.

Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. *Nature communications*, 16(1), 512.

Wang Q, et al. (2025) Cisplatin-Induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing Loss. *Cancer research communications*, 5(6), 994.

Lee KS, et al. (2025) Functional assessment of all ATM SNVs using prime editing and deep learning. *Cell*, 188(18), 5081.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF β complex for genomic stability. *Cell reports*, 44(11), 116495.

Arends T, et al. (2024) DUX4-induced HSATII transcription causes KDM2A/B-PRC1 nuclear foci and impairs DNA damage response. *The Journal of cell biology*, 223(5).

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. *Cell reports. Medicine*, 5(2), 101376.